X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5503) 5503
Newspaper Article (554) 554
Publication (370) 370
Newsletter (257) 257
Book Review (112) 112
Magazine Article (109) 109
Trade Publication Article (64) 64
Transcript (30) 30
Book Chapter (26) 26
Book / eBook (18) 18
Web Resource (14) 14
Data Set (5) 5
Report (4) 4
Conference Proceeding (3) 3
Dissertation (3) 3
Government Document (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3970) 3970
anticoagulants (3615) 3615
index medicus (2570) 2570
anticoagulants - therapeutic use (2142) 2142
female (1786) 1786
male (1737) 1737
aged (1403) 1403
middle aged (1247) 1247
warfarin (1229) 1229
stroke (1064) 1064
atrial fibrillation (996) 996
risk factors (983) 983
anticoagulants - administration & dosage (923) 923
prevention (886) 886
anticoagulants - economics (850) 850
thromboembolism (816) 816
anticoagulants - adverse effects (798) 798
adult (740) 740
cardiac & cardiovascular systems (722) 722
treatment outcome (713) 713
cost-benefit analysis (683) 683
aged, 80 and over (677) 677
pharmacology & pharmacy (673) 673
hematology (619) 619
analysis (616) 616
drug therapy (602) 602
management (601) 601
warfarin - therapeutic use (585) 585
care and treatment (582) 582
venous thromboembolism (577) 577
mortality (574) 574
peripheral vascular disease (570) 570
patients (567) 567
atrial fibrillation - drug therapy (565) 565
thrombosis (563) 563
medicine, general & internal (558) 558
research (536) 536
anticoagulation (520) 520
stroke - prevention & control (501) 501
cardiac arrhythmia (497) 497
therapy (497) 497
risk (492) 492
retrospective studies (482) 482
medicine & public health (479) 479
heparin (470) 470
surgery (467) 467
health aspects (465) 465
deep-vein thrombosis (454) 454
administration, oral (430) 430
dabigatran (429) 429
atrial fibrillation - complications (404) 404
cardiology (395) 395
molecular-weight heparin (388) 388
animals (374) 374
medical research (366) 366
rivaroxaban (363) 363
time factors (350) 350
hemorrhage - chemically induced (339) 339
risk assessment (338) 338
atrial-fibrillation (336) 336
studies (335) 335
medicine (329) 329
cost-effectiveness (319) 319
aspirin (315) 315
dosage and administration (314) 314
clinical trials (305) 305
usage (304) 304
internal medicine (303) 303
prospective studies (302) 302
stroke prevention (301) 301
abridged index medicus (300) 300
heparin, low-molecular-weight - therapeutic use (295) 295
venous thromboembolism - prevention & control (295) 295
warfarin - administration & dosage (295) 295
hospitals (293) 293
pulmonary-embolism (291) 291
international normalized ratio (286) 286
heparin - therapeutic use (278) 278
thromboembolism - prevention & control (278) 278
medicine, experimental (276) 276
pulmonary embolism (276) 276
glycosaminoglycans (274) 274
stroke - etiology (274) 274
risk-factors (270) 270
warfarin - economics (264) 264
unfractionated heparin (262) 262
prophylaxis (256) 256
united states (256) 256
warfarin - adverse effects (255) 255
drug dosages (252) 252
hemorrhage (251) 251
anticoagulants - pharmacology (249) 249
venous thrombosis (249) 249
metaanalysis (243) 243
prevalence (240) 240
health care sciences & services (238) 238
platelet aggregation inhibitors - therapeutic use (238) 238
anticoagulant (237) 237
oral anticoagulants (237) 237
antithrombotic therapy (234) 234
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6368) 6368
French (44) 44
German (36) 36
Spanish (29) 29
Portuguese (13) 13
Russian (13) 13
Italian (10) 10
Swedish (9) 9
Danish (4) 4
Dutch (4) 4
Japanese (4) 4
Chinese (2) 2
Finnish (2) 2
Hungarian (2) 2
Polish (2) 2
Turkish (2) 2
Bosnian (1) 1
Czech (1) 1
Hebrew (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Kidney International, ISSN 0085-2538, 03/2018, Volume 93, Issue 3, pp. 753 - 760
Catheter-related infections and dysfunction are the main catheter complications causing morbidity and mortality in hemodialysis patients. However, there are no... 
hemodialysis | tunneled catheter | taurolidine | catheter dysfunction | catheter-related infection | urokinase | ONCOLOGY-GROUP | METAANALYSIS | 4-PERCENT | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | ANTIMICROBIAL LOCK | HEPARIN | TRISODIUM CITRATE | BACTEREMIA | UROLOGY & NEPHROLOGY | VASCULAR ACCESS | Drug Costs | Urokinase-Type Plasminogen Activator - therapeutic use | Prospective Studies | Taurine - economics | Humans | Middle Aged | Anticoagulants - economics | Heparin - therapeutic use | Male | Renal Dialysis - economics | Thiadiazines - adverse effects | Catheters, Indwelling - economics | Equipment Design | Thiadiazines - therapeutic use | Catheter-Related Infections - prevention & control | Thiadiazines - economics | Cost Savings | Austria | Time Factors | Fibrinolytic Agents - therapeutic use | Catheters, Indwelling - adverse effects | Catheter Obstruction - etiology | Heparin - economics | Adult | Female | Catheter-Related Infections - diagnosis | Taurine - therapeutic use | Catheterization, Central Venous - adverse effects | Taurine - adverse effects | Taurine - analogs & derivatives | Anti-Infective Agents - adverse effects | Catheter-Related Infections - economics | Risk Factors | Anti-Infective Agents - therapeutic use | Anticoagulants - therapeutic use | Central Venous Catheters - adverse effects | Treatment Outcome | Catheterization, Central Venous - economics | Central Venous Catheters - economics | Fibrinolytic Agents - economics | Catheter-Related Infections - microbiology | Cost-Benefit Analysis | Anti-Infective Agents - economics | Aged | Urokinase-Type Plasminogen Activator - economics | Catheter Obstruction - economics | Catheterization, Central Venous - instrumentation | Equipment Failure | Hypertension | Comorbidity | Hemodialysis | Cardiovascular disease | Infections | Catheters | Morbidity | Citric acid | U-Plasminogen activator | Studies | Microorganisms | Antibiotics | Diabetes | Kidney diseases | Heparin | Veins & arteries
Journal Article
Value in Health, ISSN 1098-3015, 2013, Volume 16, Issue 4, pp. 498 - 506
Abstract Objectives The primary objective was to assess the cost-effectiveness of new oral anticoagulants compared with warfarin in patients with nonvalvular... 
Internal Medicine | anticoagulants | cost-effectiveness | atrial fibrillation | cardiovascular | warfarin | MORTALITY | MANAGEMENT | ASPIRIN | PROPHYLAXIS | DABIGATRAN ETEXILATE | RISK-FACTOR | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | ECONOMICS | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Warfarin - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Rivaroxaban | Atrial Fibrillation - economics | Benzimidazoles - administration & dosage | Time Factors | beta-Alanine - economics | Aged, 80 and over | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Cardiovascular Diseases - etiology | Administration, Oral | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Stroke - etiology | Hemorrhage - chemically induced | Drug Costs | Markov Chains | Age Factors | Anticoagulants - administration & dosage | Anticoagulants - economics | Thiophenes - administration & dosage | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Pyridones - administration & dosage | Thiophenes - economics | Cardiovascular Diseases - economics | Stroke - prevention & control | Hemorrhage - epidemiology | Morpholines - administration & dosage | Stroke - economics | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Pyrazoles - economics | Randomized Controlled Trials as Topic | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use
Journal Article
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2014, Volume 127, Issue 11, pp. 1075 - 1082.e1
Journal Article
PharmacoEconomics, ISSN 1170-7690, 6/2014, Volume 32, Issue 6, pp. 601 - 612
Atrial fibrillation is a major risk factor for stroke, which causes thousands of deaths and sequelae. It is recommended that atrial fibrillation patients at... 
Quality of Life Research | Health Economics | Health Administration | Public Health | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | PREDICTING STROKE | MORTALITY | POPULATION | COST-EFFECTIVENESS | HEART-FAILURE | RISK STRATIFICATION SCHEMES | TASK-FORCE | HEALTH CARE SCIENCES & SERVICES | PHARMACOLOGY & PHARMACY | HEALTH POLICY & SERVICES | ECONOMICS | HEALTH-CARE | THROMBOEMBOLISM | ISCHEMIC-STROKE | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Humans | Anticoagulants - economics | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - therapeutic use | Rivaroxaban | Atrial Fibrillation - economics | beta-Alanine - economics | Aged, 80 and over | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | Decision Support Techniques | Stroke - economics | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Anticoagulants - adverse effects | Pyrazoles - economics | Norway | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Stroke (Disease) | Care and treatment | Usage | Abnormalities | Analysis | Anticoagulants (Medicine) | Muscle contraction | Risk factors | Studies | Cardiac arrhythmia | Anticoagulants | Markov analysis | Benefit cost analysis | Original
Journal Article
Stroke, ISSN 0039-2499, 06/2013, Volume 44, Issue 6, pp. 1676 - 1681
Background and Purpose-To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral... 
Intracranial hemorrhage | Stroke | Anticoagulation | Markov model | Cost-effectiveness | Atrial fibrillation | cost-effectiveness | ANTICOAGULATION CONTROL | QUALITY | anticoagulation | stroke | ASPIRIN | CLINICAL NEUROLOGY | PROPHYLAXIS | atrial fibrillation | HEART-DISEASE | BENEFIT | THERAPY | intracranial hemorrhage | SCORES | PERIPHERAL VASCULAR DISEASE | UPDATE | UTILITY | Thiophenes - therapeutic use | Markov Chains | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | United States | Humans | Anticoagulants - economics | Thiophenes - administration & dosage | Warfarin - economics | Benzimidazoles - economics | Dabigatran | Morpholines - economics | Warfarin - administration & dosage | Warfarin - therapeutic use | Dose-Response Relationship, Drug | Pyridones - administration & dosage | Rivaroxaban | Benzimidazoles - administration & dosage | beta-Alanine - economics | Stroke - epidemiology | Thiophenes - economics | Pyridones - economics | beta-Alanine - analogs & derivatives | Morpholines - therapeutic use | Benzimidazoles - therapeutic use | Quality-Adjusted Life Years | Stroke - prevention & control | Administration, Oral | Morpholines - administration & dosage | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - administration & dosage | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Models, Statistical | Pyrazoles - economics | Pyrazoles - administration & dosage | Cost-Benefit Analysis | Aged | Pyridones - therapeutic use | Cohort Studies
Journal Article
Journal Article
JAMA, ISSN 0098-7484, 11/2014, Volume 312, Issue 20, pp. 2135 - 2145
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Clinical Drug Investigation, ISSN 1173-2563, 1/2014, Volume 34, Issue 1, pp. 9 - 17
Journal Article